Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

Cassava Sciences has faced a lot of scrutiny, with key figures resigning and the company settling an SEC penalty. Read what ...

Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first ...

The small sample size of 10 patients with rosacea limits the generalizability of the findings, and the study's open-label design may introduce bias in the clinical assessments. Further research with ...

After the speakers' presentation, there will be a question-and-answer session. [Operator instructions] Again as a reminder, today's conference is being recorded. At this time, I would like to turn the ...

Clinical trials are a significant part of the drug development cycle. However, the process has remained unchanged in recent ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...

Of the 6609 patients who had undergone randomization in the active trial, 4891 (74%) were enrolled in the post-trial period. During this period, the use of open-label SGLT2 inhibitors was similar ...

Disc Medicine has announced a US Food and Drug Administration (FDA) agreement on the regulatory path for its investigational ...

The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.

Cassava Sciences' RETHINK-ALZ trial is nearing data release. See why SAVA stock could see volatility depending on trial ...